| 59.98 0 (0%) | 11-29 13:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 70.05 | 1-year : | 81.82 |
| Resists | First : | 59.97 | Second : | 70.05 |
| Pivot price | 59.95  |
|||
| Supports | First : | 59.66 | Second : | 59.47 |
| MAs | MA(5) : | 59.97 | MA(20) : | 59.91 |
| MA(100) : | 45.51 |
MA(250) : | 31.1 |
|
| MACD | MACD : | 0.9  |
Signal : | 1.2 |
| %K %D | K(14,3) : | 100 | D(3) : | 100 |
| RSI | RSI(14): 79.7 | |||
| 52-week | High : | 59.97 | Low : | 4.86 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LBPH ] has closed below upper band by 39.3%. Bollinger Bands are 98% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 60.12 - 60.42 | 60.42 - 60.66 |
| Low: | 59.14 - 59.55 | 59.55 - 59.89 |
| Close: | 59.41 - 60.03 | 60.03 - 60.53 |
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Tue, 17 Dec 2024
Longboard Pharmaceuticals' SWOT analysis: bexicaserin potential drives stock outlook - Investing.com
Thu, 07 Nov 2024
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - Business Wire
Mon, 14 Oct 2024
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline - Business Wire
Thu, 26 Sep 2024
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome - Business Wire
Fri, 20 Sep 2024
Longboard Stock Soars on FDA Designations for Epilepsy Drug - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 121.4 (%) |
| Shares Short | 1,930 (K) |
| Shares Short P.Month | 5,170 (K) |
| EPS | -2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.8 % |
| Return on Equity (ttm) | -46.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -66 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -26.66 |
| PEG Ratio | 0 |
| Price to Book value | 8.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -31.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|